B

Bicycle Therapeutics plc (BCYC)

NMS – Real vaqt narxi. Valyuta: USD

4.72

+0.02 (0.43%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

B

Bicycle Therapeutics plc (BCYC)

NMS – Real vaqt narxi. Valyuta: USD

4.72

+0.02 (0.43%)

Yopilishda: May 12, 2026, 4:00 PM EDT

30.04.2026

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “The data we reported in the first quarter continues to provide further validation of the potential of our Bicycle technology to deliver oncology th.

21.04.2026

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago. Presentation Details: Title: Interim analysis results from.

20.04.2026

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. “EphA2 is a potentially high value target that is widely expressed in cancer and has been considered undruggable following the failure of mu.

16.04.2026

Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade

The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

24.03.2026

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)

Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

23.03.2026

Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

18.03.2026

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations of five abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego. Presentation Details: Title: Preclinical assessment of BT552.

Videolar

No Data

There is no data to display

Press-relizlar

30.04.2026

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “The data we reported in the first quarter continues to provide further validation of the potential of our Bicycle technology to deliver oncology th.

21.04.2026

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago. Presentation Details: Title: Interim analysis results from.

20.04.2026

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. “EphA2 is a potentially high value target that is widely expressed in cancer and has been considered undruggable following the failure of mu.

18.03.2026

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations of five abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego. Presentation Details: Title: Preclinical assessment of BT552.

Search stocks

Bicycle Therapeutics plc (BCYC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bicycle Therapeutics plc (BCYC)

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)

Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

Videolar

No Data

Press-relizlar

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026